ATM and ductal breast carcinoma in situ: There were an additional 82 patients with deleterious mutations detected on multigene panel testing: 31 CHEK2 (1 CPM with invasive OM, 1 CPM with DCIS), 22 PALB2 (2 CPM with invasive OM), 17 ATM (1 CPM with DCIS), 7 CDH1, 3 TP53 (1 CPM with invasive OM), and 2 PTEN (1 CPM with DCIS).